Skip to main content

Table 1 sMer, sTyro3 and sAxl ELISA demographic data

From: Increased soluble phagocytic receptors sMer, sTyro3 and sAxl and reduced phagocytosis in Juvenile-onset Systemic Lupus Erythematosus

Demographics sMer measurement in JSLE patients (n  = 15) sTyro3 measurement in JSLE patients (n  = 30) sAxl measurement in JSLE patients (n =  14)
Number (%) female 9 (60%) 22 (73%) 11 (79%)
Ethnicity, number    
White British 10 21 10
Asian 5 9 4
Age at sampling, mean (range) years 14.2 (3.5 – 18.7) 14.0 (7.5 - 17.9) 15.5 (10.7-19.4)
Disease duration, mean (range) years 3.0 (0.4 – 9.1) 3.1 (0 – 11.8) 3.5 (0 – 11.5)
Biomarker/disease activity parameter, mean (range)    
ESR, mm/hour (normal 2-8 mm/hour) 15 (1 – 60) 18.5 (<1 – 108) 12.6 (1-50)
CRP, mg/litre (normal 0-8 mg/litre) 11.2 (<4 – 78.9) 6.4 (<4 – 43.3) 4.1 (4-5.6)
C3, gm/litre (normal 1.1 – 1.9) 0.8 (0.5 – 1.4) 1.3 (0.6 – 10.9) 1.1 (0.4 – 1.4)
C4, gm/litre (normal 0.19 – 0.56) 0.14 (0.09 – 0.34) 0.15 (0.08 – 0.46) 0.2 (0.05 – 0.5)
Anti-dsDNA titre, IU/ml (normal <7) 3.1 (14 – 32) 4.9 (0 – 58) 424 (0 – 5408)
C-HAQ score, 0-3, mean (range) 0.27 (0.13 – 2.38) 0.44 (0 – 2.38) 0.64 (0 – 2.25)
Physician’s global assessment of disease activity by VAS, mean (range) mm 19 (5 – 80) 19.4 (0 – 85) 25 (0 – 70)
BILAG-2004    
Number with grade A or grade B 5 11 6
Score, mean (range) 2.6 (1 – 15) 2.9 (0 – 19) 3.8 (0 – 9)
Current medications, number of patients    
Hydroxychloroquine 13 19 10
Methotrexate 0 3 0
Azathioprine 3 4 3
Mycophenolate mofetil 8 13 7
Prednisolone 11 13 6
Prednisolone dosage, mean (range) mg/day 7.4 (1 – 30) 14.4 (3 – 40) 15.8 (2 – 60)
Rituximab 1 0 1
Infliximab 1 2 2
  1. This table presents the demographics, disease and therapeutic profiles, and clinical biomarker results of the JSLE group. Any JSLE patients with a BILAG score of A or B for any organ system at the time of sample collection were considered to have active disease.